News from isis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the...

Feb 27, 2015, 09:30 ET
Isis Pharmaceuticals, Inc.

Isis Reports Financial Results and Highlights for 2014

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced it significantly outperformed both its pro forma net operating loss (NOL) guidance and...

Feb 24, 2015, 10:46 ET
Isis Pharmaceuticals, Inc.

ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-PKKRx.  In this study, healthy...

Feb 20, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:        Isis...

Feb 10, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $5 million milestone payment from Biogen Idec associated with the...

Feb 05, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating...

Feb 04, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

Feb 03, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in patients with type 2...

Jan 14, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the...

Jan 08, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Company expects to significantly improve upon its 2014 financial...

Jan 06, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the appointment of Paula Soteropoulos as president and chief executive officer (CEO) of...

Jan 05, 2015, 18:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Sarah Boyce has joined the company as chief business officer.  In this...

Jan 05, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc....

Jan 02, 2015, 11:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

Dec 16, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy...

Dec 07, 2014, 14:05 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today final data from its Phase 2 comparator-controlled study evaluating the incidence of...

Dec 05, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award

 Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been...

Dec 03, 2014, 17:05 ET
Isis Pharmaceuticals, Inc.

ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from a Phase 2 study of ISIS-APOCIIIRx in patients with familial...

Nov 25, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120...

Nov 20, 2014, 16:47 ET
Isis Pharmaceuticals, Inc.

ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from two drugs in its anti-cancer franchise will be presented by...